{"generic":"Meningococcal Polysaccharide Vaccine, Diphtheria Conjugate","drugs":["Menactra","Meningococcal Polysaccharide Vaccine, Diphtheria Conjugate"],"mono":{"0":{"id":"jxa0s0","title":"Generic Names","mono":"Meningococcal Polysaccharide Vaccine, Diphtheria Conjugate"},"1":{"id":"jxa0s1","title":"Dosing and Indications","sub":{"0":{"id":"jxa0s1b4","title":"Adult Dosing","mono":"<ul><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (through age 55 years) 0.5 mL IM single dose (manufacturer dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (through age 55 years with high-risk conditions) 0.5 mL IM as 2-dose series, given at least 2 months apart (guideline dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (revaccination of adults who remain at increased risk for infection) 0.5 mL IM every 5 years<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (56 years or older, revaccination of person previously vaccinated with Menactra(R)) 0.5 mL IM<\/li><\/ul>"},"1":{"id":"jxa0s1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (9 to 23 months of age): 0.5 mL IM as 2-dose series, given at least 3 months apart (manufacturer dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (9 months through 23 months of age with persistent complement component deficiency, who have not received a complete vaccine series) 2-dose series, given at least 12 weeks apart<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (2 years or older with high-risk conditions, who have not received a complete vaccine series) 2-dose series, given at least 8 weeks apart; for children with asplenia, including sickle cell disease, administer vaccination at least 4 weeks following the completion of the 13-valent pneumococcal vaccine series (guideline dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (2 years or older) 0.5 mL IM single dose (manufacturer dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (11 through 12 years) give single dose followed by a booster dose at age 16 years (guideline dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> (11 through 18 years, with HIV) 2-dose series, given at least 8 weeks apart (guideline dose)<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> Catch-up: Administer at 13 to 18 years if not previously vaccinated (guideline dose).<\/li><li><b>Meningococcal infectious disease; Prophylaxis:<\/b> Catch-up: If first dose given at age 13 to 15 years, give booster dose at age 16 to 18 years, allowing at least 8 weeks between doses; if first dose is given at age 16 years or older, a booster dose is not required (guideline dose).<\/li><\/ul>"},"3":{"id":"jxa0s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Meningococcal infectious disease; Prophylaxis<br\/>"}}},"3":{"id":"jxa0s3","title":"Contraindications\/Warnings","sub":[{"id":"jxa0s3b9","title":"Contraindications","mono":"severe allergic reaction (eg, anaphylaxis) following a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid-, or CRM197-containing vaccine, or to any component of the product <br\/>"},{"id":"jxa0s3b10","title":"Precautions","mono":"<ul><li>allergic reactions, including immediate reactions and anaphylaxis may occur; appropriate supportive medical treatment should be readily available during treatment<\/li><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>Guillain-Barre syndrome (GBS), history; may increase risk of GBS following vaccination<\/li><li>immunocompromised patients, including those receiving concomitant immunosuppressant therapy (eg, irradiation, antimetabolites, alkylating agents, cytotoxic agents, and corticosteroids used in greater than physiologic doses); may have a diminished vaccine response<\/li><li>report suspected adverse events to VAERS at 1-800-822-7967 or http:\/\/vaers.hhs.gov<\/li><\/ul>"},{"id":"jxa0s3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"jxa0s3b12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"jxa0s4","title":"Drug Interactions","sub":{"1":{"id":"jxa0s4b14","title":"Major","mono":"<ul><li>Cyclosporine (theoretical)<\/li><li>Measles Virus Vaccine, Live (probable)<\/li><\/ul>"}}},"5":{"id":"jxa0s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (10.9% to 21.8% (age 2 to 55 years); 30% (age 9 to 12 months)), Injection site induration (15.7% to 18.9% (age 2 to 55 years)), Injection site pain (45% to 59.2% (age 2 to 55 years); 48.5% (age 12 months); 37.4% (age 9 months)), Swelling at injection site (10.8% to 17.4% (age 9 months to 55 years))<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (11.1% to 16% (age 2 to 55 years)), Loss of appetite (8.2% to 11.8% (age 2 to 55 years); 35.7% (age 12 months); 30.2% (age 9 months)), Vomiting (11% (age 12 months); 14.1% (age 9 months))<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (6.8% to 19.8% (age 2 to 55 years))<\/li><li><b>Neurologic:<\/b>Headache (35.6% to 41.4% (age 11 to 55 years)), Somnolence (10.8% (age 2 to 10 years); 39.8% (age 12 months); 30.2% (age 9 months))<\/li><li><b>Psychiatric:<\/b>Crying, excessive (40% (age 12 months); 33.3% (age 9 months))<\/li><li><b>Other:<\/b>Fatigue (30% to 34.7% (age 11 to 55 years)), Fever (1.5% to 5.2% (age 2 to 55 years); 24.5% (age 12 months); 12.2% (age 9 months)), Irritability (12.4% (age 2 to 10 years); 64.8% (age 12 months); 56.8% (age 9 months)), Malaise (21.9% to 23.6% (age 11 to 55 years))<\/li><\/ul>"},"6":{"id":"jxa0s6","title":"Drug Name Info","sub":{"0":{"id":"jxa0s6b17","title":"US Trade Names","mono":"Menactra<br\/>"},"2":{"id":"jxa0s6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jxa0s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jxa0s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jxa0s7","title":"Mechanism Of Action","mono":"Diphtheria toxoid conjugate vaccine is a quadrivalent meningococcal vaccine that confers active immunity by stimulating the production of antibodies against capsular polysaccharide antigens of Neisseria meningitidis serogroups A, C, Y, and W-135 conjugated to the diphtheria toxoid protein.<br\/>"},"9":{"id":"jxa0s9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IM use only; do not give subQ or IV<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>do not mix with other vaccines in the same syringe; use separate syringes at separate injection sites<\/li><li>(children 2 years or older with functional or anatomic asplenia) interval of at least 4 weeks between completion of 13-valent pneumococcal conjugate vaccine series and receipt of Menactra(R) meningococcal conjugate vaccine<\/li><\/ul><\/li><\/ul>"},"11":{"id":"jxa0s11","title":"How Supplied","mono":"<b>Menactra<\/b><br\/>Intramuscular Suspension: 16 MCG\/0.5 ML<br\/>"},"13":{"id":"jxa0s13","title":"Clinical Teaching","mono":"<ul><li>This vaccine may cause injection site pain or tenderness, irritability, diarrhea, drowsiness, loss of appetite, headache, and fatigue.<\/li><li>Instruct parents\/guardians and\/or patients to immediately report signs\/symptoms of allergic reaction or Guillain-Barre syndrome (eg, muscle weakness, numbness, tingling).<\/li><\/ul>"}}}